Strs Ohio Has $1.64 Million Stock Holdings in DaVita Inc. $DVA

Strs Ohio increased its position in shares of DaVita Inc. (NYSE:DVA) by 23.5% during the second quarter, Holdings Channel reports. The institutional investor owned 11,531 shares of the company’s stock after purchasing an additional 2,191 shares during the quarter. Strs Ohio’s holdings in DaVita were worth $1,643,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. grew its position in DaVita by 3.4% during the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock worth $251,322,000 after buying an additional 53,402 shares in the last quarter. Northern Trust Corp boosted its holdings in DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after purchasing an additional 149,858 shares in the last quarter. Gates Capital Management Inc. boosted its holdings in DaVita by 0.7% during the first quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after purchasing an additional 4,698 shares in the last quarter. Amundi boosted its holdings in DaVita by 16.0% during the first quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after purchasing an additional 71,304 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in DaVita by 10.7% during the first quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock valued at $62,400,000 after purchasing an additional 39,485 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Up 0.8%

NYSE:DVA opened at $120.06 on Wednesday. DaVita Inc. has a 1 year low of $115.39 and a 1 year high of $179.60. The firm has a 50 day moving average of $130.05 and a 200-day moving average of $136.27. The stock has a market capitalization of $8.48 billion, a P/E ratio of 12.36, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last posted its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. During the same quarter last year, the firm posted $2.59 EPS. The business’s revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Ratings Changes

DVA has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Zacks Research downgraded DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Monday. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Barclays cut their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Five investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $148.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.